Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibros⦠read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
$3.94
Price+1.50%
$0.06
$195.933m
Small
98.5x
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$111.554m
-
1y CAGR-
3y CAGR-
5y CAGR$37.427m
-
1y CAGR-
3y CAGR-
5y CAGR$0.59
-
1y CAGR-
3y CAGR-
5y CAGR$69.224m
$151.424m
Assets$82.200m
Liabilities$62.133m
Debt41.0%
1.4x
Debt to EBITDA-$64.039m
-
1y CAGR-
3y CAGR-
5y CAGR